Global specialty biopharmaceutical company Mallinckrodt has enrolled patients for its Phase lV clinical trial, PODOCYTE, of acthar gel (repository corticotropin injection) for inducing remission of proteinuria due to treatment-resistant or treatment-intolerant, idiopathic, focal segmental glomerulosclerosis (FSGS).

FSGS is a rare disease that can cause nephrotic syndrome (NS), a serious kidney disorder.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Treatment of Proteinuria Due to Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A 2 Part Prospective Study of H.P. Acthar Gel (PODOCYTE) trial is a Phase lV, multicentre, randomised, double-blind, parallel group, placebo-controlled efficacy trial.

The trial’s primary endpoint is to measure complete and partial remission of proteinuria at week 24 compared with patients’ baseline.

"The trial’s primary endpoint is to measure complete and partial remission of proteinuria at week 24 compared with patients’ baseline."

It is expected to take a number of years to complete.

Mallinckrodt noted that acthar gel is an injectable drug approved by the US Food and Drug Administration (FDA) to treat 19 indications.

Out of these 19 indications, currently promoted on-label indications include inducing a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type, or that which is due to lupus erythematosus.

The injectable drug can be used for the treatment of acute exacerbations of multiple sclerosis in adults, as monotherapy to treat infantile spasms in infants and children under two years of age, during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.

Acthar can also be used during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis).

Mallinckrodt chief scientific officer and senior vice-president Dr Steven Romano said: "Mallinckrodt is committed to providing treatment options where few exist.

"Clinical experience supports the use of Acthar to induce remission of proteinuria in FSGS.

"We are pleased to enroll the first patient in the PODOCYTE trial to better understand how clinicians may utilise Acthar within the management of proteinuria in this patient population."